Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the results of the ASCERTAIN-TRD comparative effectiveness research trial for ABILIFY (aripiprazole) in patients with treatment resistant depression

Ticker(s): OTSKY

Who's the expert?

Institution: Private Practice

Manages 50 with Schizophrenia; 30 patients with Ingrezza
Familiar with the data for KarXT (xanomeline-trospium) a M1/M4- preferring muscarinic agonist being investigated for treatment in patients with Schizophrenia

Interview Goal

to discuss the current standard of care and the potential of use of ABILIFY (aripiprazole) as an add-on treatment for TRD.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.